RegulatoryCompany release
Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026
The USPTO has granted Allarity Therapeutics a patent with 36 allowed claims covering twice-daily oral stenoparib in advanced ovarian cancer and other solid tumours.
Allarity Therapeutics has been granted U.S. Patent No. 12,806,205 for stenoparib, its PARP/tankyrase inhibitor. The company announced the grant on 18 November 2026. The patent contains 36 allowed claims on twice-daily oral dosing and on methods of treating advanced ovarian cancer and other solid tumours.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Allarity Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027
Belite Bio, Inc (BLTE) · Fri 20 Nov 2026
FDA publishes new and revised draft product-specific guidances on bioequivalence for generics
🇺🇸 FDA · Fri 20 Nov 2026
Dutch inspectorate posts Biotronik field safety notice on ICD and CRT-D lithium plating
🇳🇱 IGJ · Thu 19 Nov 2026
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026
FDA publishes Q&A guidance on transferring a 510(k) clearance between holders
🇺🇸 FDA CBER · Thu 19 Nov 2026